BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30347598)

  • 1. CD45 correlates with adverse risk stratification, decreased treatment response and unfavorable survival profiles in elderly acute myeloid leukemia patients.
    Guo L; Chen L; Wang H
    Cancer Biomark; 2018; 23(3):455-463. PubMed ID: 30347598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?
    Yoon JH; Kim HJ; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):80-8. PubMed ID: 24149098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of AK1 predicts inferior prognosis in acute myeloid leukemia patients undergoing chemotherapy.
    Qin T; Zhao H; Shao Y; Hu N; Shi J; Fu L; Zhang Y
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32519744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octamer-binding transcription factor 4 correlates with complex karyotype, FLT3-ITD mutation and poorer risk stratification, and predicts unfavourable prognosis in patients with acute myeloid leukaemia.
    Xiang Y; Zhou X
    Hematology; 2018 Dec; 23(10):721-728. PubMed ID: 29950146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of A-kinase interacting protein 1 as a potential biomarker for risk and prognosis of acute myeloid leukemia.
    Yan Y; Li X; Gao J
    J Clin Lab Anal; 2020 May; 34(5):e23055. PubMed ID: 32356617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of miR-338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy.
    Fu L; Qi J; Gao X; Zhang N; Zhang H; Wang R; Xu L; Yao Y; Niu M; Xu K
    J Cell Physiol; 2019 Nov; 234(11):20704-20712. PubMed ID: 30997674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
    Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiality of Protein phosphatase Mg
    Yu M; Hu J; He D; Chen Q; Liu S; Zhu X; Li B
    J Clin Lab Anal; 2020 May; 34(5):e23171. PubMed ID: 31901183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study.
    Grosicki S; Holowiecki J; Kuliczkowski K; Skotnicki A; Hellmann A; Kyrcz-Krzemien S; Dmoszynska A; Sułek K; Kloczko J; Jedrzejczak WW; Warzocha K; Zdziarska B; Wierzbowska A; Pluta A; Komarnicki M; Giebel S
    Am J Hematol; 2015 Oct; 90(10):904-9. PubMed ID: 26149802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central Nervous System Involvement at the Time of Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with a Poor Outcome in Patients with Acute Myeloid Leukemia.
    Ikegawa S; Doki N; Kaito S; Kurosawa S; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Watanabe D; Hagino T; Yoshioka K; Watakabe K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
    Pathol Oncol Res; 2017 Apr; 23(2):433-437. PubMed ID: 28004352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
    Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia.
    Wang SY; Cheng WY; Mao YF; Zhu YM; Liu FJ; Ma TT; Shen Y
    Hematol Oncol; 2019 Oct; 37(4):456-463. PubMed ID: 31348835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
    Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A-kinase interacting protein 1 might serve as a novel biomarker for worse prognosis through the interaction of chemokine (C-X-C motif) ligand 1/chemokine (C-X-C motif) ligand 2 in acute myeloid leukemia.
    Hao X; Gu M; Sun J; Cong L
    J Clin Lab Anal; 2020 Feb; 34(2):e23052. PubMed ID: 31617252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.
    Yang J; Cai Y; Jiang J; Wan L; Bai H; Zhu J; Li S; Wang C; Song X
    Ann Hematol; 2018 Mar; 97(3):497-507. PubMed ID: 29250743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia.
    Zhou JD; Zhang TJ; Xu ZJ; Gu Y; Ma JC; Li XX; Guo H; Wen XM; Zhang W; Yang L; Liu XH; Lin J; Qian J
    Diagn Pathol; 2019 Jun; 14(1):68. PubMed ID: 31253168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.